1
|
Witkowski Durand Viel P, Henry K, Morel J, Jacot W, Jorgensen C, Riviere S, Maria ATJ, Rigau V, Le Quellec A, Goulabchand R, Guilpain P. Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren's syndrome. Cancer Immunol Immunother 2023; 72:4309-4322. [PMID: 37938369 DOI: 10.1007/s00262-023-03565-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 10/17/2023] [Indexed: 11/09/2023]
Abstract
OBJECTIVE While the incidence and type of blood malignancies are well documented amid primary Sjögren's syndrome patients (pSS), data focusing on solid neoplasms are more conflicting. We aimed to describe clinical, pathological, and immunological characteristics of pSS patients with cancers, along with the chronological interplay between the two conditions. METHODS Outcomes concerning both pSS and cancer were retrospectively collected from Montpellier University Hospital (tertiary center) between 2019 and 2020. pSS characteristics were compared to a control group of pSS patients without cancer. RESULTS A total of 165 patients with pSS were included: 55 patients with cancer (52 female, mean age 58.4 ± 10.4 years at pSS diagnosis; mean follow-up 10.5 ± 10.1 years, 12 patients had multiple cancers) and 110 controls without cancer. Characteristics of pSS patients with cancers were different from controls mostly for lymphoma prognosis factors. Among the 70 cancers, we recorded 55 solid neoplasms (whom 27 breast cancers and 8 lung cancers, and 82% of adenocarcinomas), with no evidence of disease at the end of follow-up in 85% of them. Among the 15 recorded blood malignancies, ten were lymphomas with an excellent prognosis. Regarding chronological interplay between cancer and pSS, most cancers (43%) were diagnosed close (± 5 years) to pSS diagnosis. Breast cancers were diagnosed before or close to pSS diagnosis (mean delay - 1.8 ± 13.0 years), at an early stage, with only two relapses (no cancer-related death), while lung cancers were diagnosed late after. CONCLUSIONS The tight chronological interplay between breast cancer and pSS and the intriguing pathological and immunological pattern of pSS in these patients suggest a hypothesis of immune control of cancer.
Collapse
Affiliation(s)
- Philine Witkowski Durand Viel
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
- Faculty of Medicine, University of Montpellier, Montpellier, France
| | - Kim Henry
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - Jacques Morel
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Department of Rheumatology, Montpellier University Hospital, IDESP, Montpellier, France
| | - William Jacot
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Medical Oncology, Montpellier Cancer Institute (ICM) Val d'Aurelle, Montpellier, France
| | - Christian Jorgensen
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Institute for Regenerative Medicine & Biotherapy, University of Montpellier, Montpellier, France
- Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Montpellier University Hospital, Montpellier, France
| | - Sophie Riviere
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
| | - Alexandre Thibault Jacques Maria
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Institute for Regenerative Medicine & Biotherapy, University of Montpellier, Montpellier, France
| | - Valérie Rigau
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Department of Biopathology, Biopathology Tumor Bank, Montpellier University Hospital, Montpellier, France
| | - Alain Le Quellec
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France
- Faculty of Medicine, University of Montpellier, Montpellier, France
| | - Radjiv Goulabchand
- Faculty of Medicine, University of Montpellier, Montpellier, France
- Institute for Regenerative Medicine & Biotherapy, University of Montpellier, Montpellier, France
- IDESP, Univ Montpellier, INSERM, Montpellier, Nimes University Hospital, Nimes, France
- Department of Internal Medicine, University Hospital, Nimes, France
| | - Philippe Guilpain
- Department of Internal Medicine - Multi-organ Diseases, St Eloi Hospital, Montpellier University Hospital, Univ Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
- Faculty of Medicine, University of Montpellier, Montpellier, France.
- Institute for Regenerative Medicine & Biotherapy, University of Montpellier, Montpellier, France.
| |
Collapse
|
2
|
Rivet V, Riviere S, Goulabchand R, Suzon B, Henneton P, Partouche L, Rullier P, Quellec AL, Konate A, Schiffmann A, Vincent T, Ziane R, Flori N, Picot MC, Sultan A, Maria ATJ, Guilpain P. High prevalence of malnutrition in systemic sclerosis: Results from a French monocentric cross-sectional study. Nutrition 2023; 116:112171. [PMID: 37837826 DOI: 10.1016/j.nut.2023.112171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 07/08/2023] [Accepted: 07/23/2023] [Indexed: 10/16/2023]
Abstract
OBJECTIVES Systemic sclerosis (SSc) can cause malnutrition due to frequent gastrointestinal involvement. However, prevalence of malnutrition in SSc is poorly known. The aim of this study was to evaluate the prevalence of malnutrition in SSc and its potential associations with disease features in patients from a tertiary referral center. METHODS All patients meeting American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for SSc followed between January 1, 1985, and January 1, 2019, at the Department of Internal Medicine, Saint Eloi University Hospital, were included. Malnutrition was assessed using the 2020 French recommendations for SSc and the malnutrition universal screening tool score. Severe malnutrition was defined via the French Haute Autorité de Santé (National Health Authority) 2007 criteria. RESULTS A total of 120 patients were included, with mean age 64 (± 15) y and a female-to-male sex ratio of 5:1. According to 2020 French recommendations, 71 patients (59.2%) were malnourished and 30 (25%) had at least one criterion of severe malnutrition. With the malnutrition universal screening tool score, 41.7%, 20%, and 38.3%, respectively, had low, medium, and high risk of malnutrition. Multivariate analysis revealed the following results: 1) malnutrition was associated with cardiac involvement (P < 0.01); 2) a high malnutrition universal screening tool score was also associated with specific cardiac involvement (P < 0.01); and 3) severe malnutrition was strongly correlated with interincisal distance <35 mm (P = 0.02). CONCLUSIONS Malnutrition affects more than half of SSc patients and is associated with specific cardiac involvement. Interincisal distance <35 mm could be a red flag for severe malnutrition in SSc.
Collapse
Affiliation(s)
- Valérian Rivet
- Internal Medicine and Immunopathology Departement, Cancer University of Toulouse Oncopole, University Hospital Center of Toulouse, Toulouse, France
| | - Sophie Riviere
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Radjiv Goulabchand
- Montpellier University Hospital, Montpellier, France; Departement of Internal Medicine, University Hospital Center of Nîmes, Nîmes, France
| | - Benoît Suzon
- Department of Internal Medicine, University Hospital of Martinique, Fort-de-France, Martine, France
| | - Pierrick Henneton
- Montpellier University Hospital, Montpellier, France; Vascular Department of Internal Medicine, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Léo Partouche
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Patricia Rullier
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Alain Le Quellec
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France; Montpellier University Hospital, Montpellier, France
| | - Amadou Konate
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Aurélie Schiffmann
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Thierry Vincent
- Immunology Laboratory, Department of Immunology, Saint-Eloi Hospital, CHRU Montpellier, France
| | - Rahima Ziane
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France
| | - Nicolas Flori
- Gastroenterology Unit, Department of Gastroenterology and Nutrition, Cancer Institute of Montpellier, Montpellier, France
| | - Marie Christine Picot
- Montpellier University Hospital, Montpellier, France; Clinical Research and Epidemiology Unit, Medical Information Department, INSERM, Clinical Investigator Center, University Hospital Center of Montpellier, Montpellier, France
| | - Ariane Sultan
- Montpellier University Hospital, Montpellier, France; Diabetes Nutrition Unit, Endocrinology Department, Lapeyronie Hospital, University Hospital Center of Montpellier, Montpellier, France; PhyMedExp, Montpellier University, INSERM, CNRS, University Hospital Center of Montpellier, Montpellier, France
| | - Alexandre Thibaut Jacques Maria
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France; Montpellier University Hospital, Montpellier, France; Department of Internal Medicine and Immuno-Oncology (MEDI²O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France.
| | - Philippe Guilpain
- Department of Internal Medicine: Multi-Organic Diseases, Saint-Eloi Hospital, University Hospital Center of Montpellier, Montpellier, France; Montpellier University Hospital, Montpellier, France
| |
Collapse
|
3
|
Moyon Q, Pineton de Chambrun M, Gousseff M, Mathian A, Hie M, Urbanski G, Verlicchi F, Faguer S, Dossier A, Lega JC, Riviere S, Saadoun D, Graveleau J, Lucchini-Lecomte MJ, Christides C, Le Moal S, Bibes B, Malizia G, Ruivard M, Blaison G, Alric L, Agard C, Soubrier M, Viallard JF, Levesque H, Rivard GE, Tieulie N, Hot A, Lovey PY, Hanslik T, Lhote F, Eble V, Álvarez Troncoso J, Aujayeb A, Quentric P, Taieb D, Cohen-Aubart F, Lambert M, Amoura Z. Intravenous Immunoglobulins Tapering and Withdrawal in Systemic Capillary Leak Syndrome (Clarkson Disease). J Allergy Clin Immunol Pract 2022; 10:2889-2895. [PMID: 35870726 DOI: 10.1016/j.jaip.2022.07.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 07/05/2022] [Accepted: 07/06/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND The systemic capillary leak syndrome (SCLS), also known as Clarkson disease, is a very rare condition characterized by recurrent life-threatening episodes of vascular hyperpermeability in the presence of a monoclonal gammopathy. Extended intravenous immunoglobulin (IVIG) treatment is associated with fewer recurrences and improved survival, but the optimal treatment dosage and duration remain unknown. OBJECTIVE We aim to evaluate the safety of IVIG tapering and withdrawal in patients with SCLS. METHODS We conducted a retrospective multicenter study including all adult patients with monoclonal gammopathy-associated SCLS from the EurêClark registry who received at least 1 course of IVIG. The primary end point was overall survival according to IVIG withdrawal. RESULTS Fifty-nine patients of mean ± SD age 51 ± 13 years were included. Overall cumulative probabilities of 2-, 5-, 10- and 15-year survival were 100%, 85%, 72%, 44%, respectively. The IVIG was withdrawn at least once in 18 patients (31%; W+ group) and never in 41 patients (69%; W- group). Cumulative probabilities of 10-year survival in W+ versus W- groups were 50% and 83% (log rank test, P = .02), respectively. Relapse rate and the median number of relapses in the W+ versus the W- groups were 72% versus 58% (P = 0.3) and 2.5 (0.3-4) versus 1 (0-2) (P = .03), respectively. The IVIG tapering was not statistically associated with increased person-year incidence of attacks using a mixed linear model. CONCLUSIONS The IVIG withdrawal was associated with increased mortality and higher rate of recurrence in SCLS patients. The IVIG tapering might be cautiously considered in stable SCLS patients.
Collapse
Affiliation(s)
- Quentin Moyon
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France
| | - Marc Pineton de Chambrun
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France; Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), and AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.
| | - Marie Gousseff
- Service de médecine interne, Centre Hospitalier (CH) Bretagne Atlantique, Vannes, France
| | - Alexis Mathian
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | - Miguel Hie
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | - Geoffrey Urbanski
- Service de Médecine Interne et d'Immunologie Clinique, Centre Hospitalier Universitaire (CHU) d'Angers, Angers, France
| | | | - Stanislas Faguer
- Département de Néphrologie Et Transplantation D'organes, Centre de Référence Des Maladies Rénales Rares, INSERM U1297 (I2MC, équipe 12), CHU de Toulouse, Toulouse, France
| | - Antoine Dossier
- Service de médecine interne, CHU Bichat, APHP, Paris, France
| | - Jean-Christophe Lega
- Service de médecine interne et pathologies vasculaires, CHU Lyon Sud, Pierre-Bénite, Lyon; Univ Lyon 1, UMR CNRS 5558 Laboratoire de Biologie et Biométrie Evolutive
| | - Sophie Riviere
- Service de médecine interne, Hôpital S(t)-Eloi, CHRU, Montpellier, France
| | - David Saadoun
- Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre National de Références Maladies Autoimmunes et Systémiques Rares, Centre National de Références Maladies Autoinflammatoires Rares et Amylose Inflammatoire, and INSERM, UMR S 959, Immunology- Immunopathology-Immunotherapy (I3), Paris, France
| | | | | | | | | | | | | | - Marc Ruivard
- Service de médecine interne, Hôpital d'Estaing, CHU de Clermont-Ferrand, France
| | - Gilles Blaison
- Service de médecine interne, Hôpital Pasteur, Colmar, France
| | - Laurent Alric
- Service de médecine interne, Pôle digestif, CHU Rangueil, Toulouse 3 University, Toulouse, France
| | - Christian Agard
- Nantes Université, CHU Nantes, service de médecine interne, F-44000 Nantes, France
| | - Martin Soubrier
- Service de rhumatologie, Hôpital Gabriel-Montpied, CHU Clermont-Ferrand, France
| | | | - Hervé Levesque
- Service de médecine interne, Normandie Université, UNIROUEN, 76031 Rouen, France
| | | | | | - Arnaud Hot
- Service de médecine interne, CHU Edouard Herriot, Lyon, France
| | | | - Thomas Hanslik
- Université Versailles Saint Quentin, APHP, CHU Ambroise Paré, Service de médecine interne, Boulogne-Billancourt, France
| | - François Lhote
- Service de médecine interne, Hôpital Delafontaine, Saint-Denis, France
| | | | - Jorge Álvarez Troncoso
- Servicio de Medicina Interna, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Universitario La Paz, Madrid, Spain
| | - Avinash Aujayeb
- Northumbria Specialist Emergency Care Hospital, Newcastle, UK
| | - Paul Quentric
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), and AP-HP, Hôpital La Pitié-Salpêtrière, Département d'Immunologie, Paris, France
| | - Dov Taieb
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France
| | - Fleur Cohen-Aubart
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | - Marc Lambert
- Univ. Lille, CHU Lille, Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), INSERM, UMR 1167, RID-AGE, F-59000 Lille, France; Univ. Lille, CHU Lille, Département de Médecine Interne et d'Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares Nord et Nord-Ouest de France (CeRAINO), European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNECT), INSERM, UMR 1167, RID-AGE, F-59000 Lille, France
| | - Zahir Amoura
- Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| |
Collapse
|
4
|
Le TTT, Martinent G, Dupuis-Girod S, Parrot A, Contis A, Riviere S, Chinet T, Grobost V, Espitia O, Dussardier-Gilbert B, Alric L, Armengol G, Maillard H, Leguy-Seguin V, Leroy S, Rondeau-Lutz M, Lavigne C, Mohamed S, Chaussavoine L, Magro P, Seguier J, Kerjouan M, Fourdrinoy S. Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT. Orphanet J Rare Dis 2022; 17:281. [PMID: 35854330 PMCID: PMC9295423 DOI: 10.1186/s13023-022-02426-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 06/30/2022] [Indexed: 12/01/2022] Open
Abstract
Background Hereditary hemorrhagic telangiectasia (HHT) disease is a rare genetic disorder with symptoms and complications that can significantly affect patients’ daily lives. To date, no scale has been validated to assess the specific symptoms of this disease on the quality of life (QOL) of HHT patients. This makes it difficult for clinicians to accurately measure the quality of life of patients with HHT. The present study aims to develop and validate a QOL measurement tool specific to HHT disease: the QOL questionnaire in HHT (QoL-HHT). Methods A quantitative, non-interventional, multi-center study involving HHT patients in twenty French HHT expert centers was conducted. A calibration sample of 415 HHT patients and a validation sample of 228 HHT patients voluntarily participated in the study. Data were analyzed using exploratory factor analysis (EFA), confirmatory factor analysis (CFA), Exploratory Structural Equation Modeling (ESEM) analyses, reliability analyses, and correlational analyses. Results The EFA, CFA and ESEM results allowed us to provide evidence of the factorial structure of a questionnaire composed of 24 items measuring 6 domains of QOL: Physical limitations, social relationships, concern about bleeding, relationship with the medical profession, experience of symptoms, and concern about the evolution of the disease. Cronbach’s alpha coefficients (> 0.70) demonstrated reliable internal consistency of all the QoL-HHT scores (dimensions). The results of the test–retest provided further evidence of the reliability of the QOL-HHT scores over time. Correlational analyses provided evidence for the convergent validity of the QoL-HHT scores. Conclusions We developed a simple and quick self-assessment tool to measure quality of life specific to HHT disease. This study demonstrated reliability and validity of our QoL-HHT scores. It is a very promising tool to evaluate the impact of HHT disease on all aspects of the quality of life of HHT patients in order to offer them individualized medico-psycho-social support. Trial registration: ClinicalTrials, NCT03695874. Registered 04 October 2018, https://www.clinicaltrials.gov/ct2/show/NCT03695874 Supplementary Information The online version contains supplementary material available at 10.1186/s13023-022-02426-2.
Collapse
Affiliation(s)
- Thi Thao Truc Le
- Laboratoire de Psychologie sur les Dynamiques Relationnelles et Processus Identitaires (EA 7458), Université de Bourgogne-Franche-Comté, 3 Allée des Stades Universitaires, 21000, Dijon, France
| | - Guillaume Martinent
- Laboratoire sur les Vulnérabilités et l'Innovation dans le Sport (EA 7428), Université de Lyon, Université Claude Bernard Lyon 1, 27-29 bd du 11 Novembre 1918, 69622, Villeurbanne, France
| | - Sophie Dupuis-Girod
- Service de génétique clinique, Centre de Référence pour la Maladie de Rendu-Osler, Hospices Civils de Lyon, HFME Bâtiment A1, 59 bd Pinel, 69677, Bron Cedex, France
| | - Antoine Parrot
- Service de pneumologie, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, 4 rue de Chine, 75790, Paris Cedex 20, France
| | - Anne Contis
- Service de médecine interne, Hôpital Saint André, 1 rue Jean Burguet, 33000, Bordeaux, France
| | - Sophie Riviere
- Service de médecine interne, CHU de Montpellier Hôpital St Eloi, Avenue A. Fliche, 34295, Montpellier Cedex 5, France
| | - Thierry Chinet
- Consultation Maladie de Rendu-Osler, CHU Ambroise Paré, 9 av Charles de Gaulle, 92104, Boulogne Billancourt, France
| | - Vincent Grobost
- Service de médecine interne, CHU Estaing, 1 rue Lucie et Raymond Aubrac, 63100, Clermont-Ferrand, France
| | - Olivier Espitia
- Service de médecine interne - médecine vasculaire, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France
| | | | - Laurent Alric
- Service de médecine interne, CHU Rangueil, 1 av du Pr Jean Poulhès, 31059, Toulouse Cedex 9, France
| | - Guillaume Armengol
- Service de médecine interne, CHU de Rouen Ch. Nicolle, , 1 rue de Germont, 76031, Rouen Cedex, France
| | - Hélène Maillard
- Service de médecine interne, Hôpital Huriez, 1 rue Michel Polonovski, 59037, LILLE Cedex, France
| | - Vanessa Leguy-Seguin
- Service de médecine interne, Hôpital Le Bocage, 2 Bd Maréchal de Lattre de Tassigny, BP 77908, 21079, Dijon Cedex, France
| | - Sylvie Leroy
- Service de pneumologie, CHU de Nice, 30 av de la Voie Romaine, 06002, Nice Cedex, France
| | - Murielle Rondeau-Lutz
- Service de médecine interne, CHU de Strasbourg Nouvel Hôpital Civil, 1 place de l'Hôpital, 67000, Strasbourg, France
| | - Christian Lavigne
- Service de médecine interne, CHU d'Angers, 4 rue Larrey, 49933, Angers Cedex 09, France
| | - Shirine Mohamed
- Service de médecine interne, CHU de Nancy, Hôpital Brabois, Rue du Morvan, 54511, Vandoeuvre Les Nancy, France
| | - Laurent Chaussavoine
- Service de médecine vasculaire, CHU de Caen, Avenue de la Côte de Nacre, 14000, Caen, France
| | - Pascal Magro
- Service de pneumologie, CHRU de Tours Hôpital Bretonneau, 2 bd Tonnellé, 37044, Tours Cedex 9, France
| | - Julie Seguier
- Service de médecine interne, Hôpital de La Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 05, France
| | - Mallorie Kerjouan
- Service de pneumologie, CHU de Rennes Hôpital Pontchaillou, 2 rue Henri Le Guilloux, 35033, Rennes Cedex 09, France
| | - Sylvie Fourdrinoy
- Service de génétique clinique, Centre de Référence pour la Maladie de Rendu-Osler, Hospices Civils de Lyon, HFME Bâtiment A1, 59 bd Pinel, 69677, Bron Cedex, France.
| |
Collapse
|
5
|
Guédon A, Carrat F, Mouthon L, Launay D, Chaigne B, Pugnet G, Lega J, Hot A, Cottin V, Agard C, Allanore Y, Fauchais A, Jego P, Dhôte R, Papo T, Chatelus E, Fain O, Mekinian A, Hachulla E, Riviere S. Atteintes cardiaques de la sclérodermie systémique : résultats d’une étude de cohorte nationale française. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.03.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Pineton de Chambrun M, Moyon Q, Faguer S, Urbanski G, Mathian A, Zucman N, Werner M, Luyt CE, Verlicchi F, Amoura Z, Gousseff M, Mauhin W, Hot A, Lega JC, Lambert M, Riviere S, Dossier A, Ruivard M, Lhote F, Blaison G, Merceron S, Zapella N, Alric L, Agard C, Lacout M, Saadoun D, Graveleau J, Soubrier M, Haroche J, Boileau J, Lucchini-Lecomte MJ, Hanslik T, Christides C, Levesque H, Talasczka A, Bulte C, Hachulla E, Decaux O, Sonneville R, Ibouanga F, Arnulf B, Benedit M, Viallard JF, Tieulie N, Haddad F, Moulin B, Cohen-Aubert F, Lovey PY, le Moal S, Bibes B, Rivard GE, Rondeau E, Malizia G, Debourdeau P, Abgueguen P, Bosseray A, Devaquet J, Presne C, Liferman F, Limal N, Argaud L, Hernu R, de la Salle S, Faguer S, Urbanski G, Zucman N, Werner M, Luyt CE, Moyon Q, Verlicchi F, Troncoso JÁ, Harty J, Godmer P, Hie M, Papo T, Hatron PY, Mathian A, Amoura Z. The consequences of COVID-19 pandemic on patients with monoclonal gammopathy-associated systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol Pract 2022; 10:626-629. [PMID: 34890829 PMCID: PMC8648572 DOI: 10.1016/j.jaip.2021.11.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 11/19/2021] [Accepted: 11/19/2021] [Indexed: 12/14/2022]
Affiliation(s)
- Marc Pineton de Chambrun
- Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Sorbonne Université, Paris, France,Institut de Cardiométabolisme et Nutrition (ICAN), INSERM, UMRS_1166-ICAN, Sorbonne Université, Paris, France,Service de Médecine Interne 2, Institut E3M, APHP, Hôpital La Pitié-Salpêtrière, Sorbonne Université Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France,Corresponding author: Marc Pineton de Chambrun, MD, MSc, Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, 47-83, boulevard de l’Hôpital, 75651 Paris Cedex 13, France
| | - Quentin Moyon
- Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Sorbonne Université, Paris, France,Service de Médecine Interne 2, Institut E3M, APHP, Hôpital La Pitié-Salpêtrière, Sorbonne Université Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | - Stanislas Faguer
- Département de Néphrologie et Transplantation d'Organes, Centre de Référence Des Maladies Rénales Rares, INSERM U1297 (I2MC, Équipe 12), Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Geoffrey Urbanski
- Service de Médecine Interne et d’Immunologie Clinique, Centre Hospitalier Universitaire, Angers, France
| | - Alexis Mathian
- Service de Médecine Interne 2, Institut E3M, APHP, Hôpital La Pitié-Salpêtrière, Sorbonne Université Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | - Noémie Zucman
- Service de Médecine Intensive Réanimation, Hôpital Louis Mourier, APHP, DMU ESPRIT, Université de Paris, Colombes, France
| | - Marie Werner
- Service de Réanimation Chirurgicale Adulte, AP-HP, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin-Bicêtre, France
| | - Charles-Edouard Luyt
- Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Sorbonne Université, Paris, France,Institut de Cardiométabolisme et Nutrition (ICAN), INSERM, UMRS_1166-ICAN, Sorbonne Université, Paris, France
| | | | - Zahir Amoura
- Service de Médecine Interne 2, Institut E3M, APHP, Hôpital La Pitié-Salpêtrière, Sorbonne Université Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-Phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ricard L, Malard F, Riviere S, Laurent C, Fain O, Mohty M, Gaugler B, Mekinian A. Le déséquilibre des lymphocytes B régulateurs est corrélé avec l’expansion des lymphocytes Tfh dans la sclérodermie systémique. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.03.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Richier Q, Jachiet V, Carrat F, Abisror N, Jerome P, Marc G, Placais L, Fayand A, Adedjouma A, Gobert D, Riviere S, Chauchard M, Gatfosse M, Chopin D, Mahévas T, Morgand M, Meynard J, Fain O, Lacombe K, Mekinian A. Efficacité du Tocilizumab dans la COVID-19 modérée à sévère : une cohorte française exposé-non exposé. Rev Med Interne 2021. [PMCID: PMC8192027 DOI: 10.1016/j.revmed.2021.03.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Introduction L’infection par le SARS-CoV-2 peut mener à un syndrome de détresse respiratoire aigu dont la mortalité était estimée à 50 % au début de l’épidémie. Ces formes sévères étant significativement associées à un état d’hyperinflammation, et notamment à un niveau élevé d’interleukine-6, il a été proposé que cibler la voie de signalisation de cette interleukine majoritairement pro-inflammatoire, puisse réduire la mortalité de la COVID-19. Pour autant, un an après le début de la pandémie, la place de ces inhibiteurs, dont le Tocilizumab, un anticorps monoclonal dirigé contre le récepteur de l’interleuline-6, reste à déterminer. Patients et méthodes Cohorte exposé-non exposé en vie réelle, monocentrique et menée à l’hôpital Saint-Antoine, Paris, France, avant la mise en place de l’essai randomisé CORIMUNO-TOCI. Etaient inclus les patients de plus de 18 ans qui présentaient une forme modérée à sévère de COVID-19, selon la définition de l’OMS, et qui nécessitaient une oxygéno-requerance ≥ 4 L/min, associée à un syndrome inflammatoire biologique (CRP > 50 mg/L). Etaient exclus les patients qui portaient des contre-indications au Tocilizumab (antécédent de sigmoïdite ou de diverticulite, une cytolyse hépatique supérieure à 5 N, une allergie connue au Tocilizumab, ou une infection bactérienne active.) Par ailleurs, les patients qui étaient transférés en soins intensifs dans les premières 24 h après l’injection de Tocilizumab étaient exclus de notre étude, puisque ils étaient inclus dans une étude qui évaluait le Tocilizumab en réanimation. Les patients du groupe Tocilizumab recevaient une injection de 8 mg/kg (maximum 800 mg) de Tocilizumab associée aux soins courants et les patients du groupe soins courants ne recevaient que les soins courants. Pour assurer la comparabilité des deux groupes nous avons utilisé le score de propension. Notre critère de jugement principal était le délai de sevrage en oxygène. Les critères de jugement secondaire étaient : le transfert en soins intensifs, le besoin de ventilation mécanique, le décès toutes causes confondues, le décès au dixie jour, la durée d’hospitalisation ainsi que les scores composites intubation ou décès et transfert en soins intensifs ou décès. Résultats Cinquante patients ont été inclus dans le groupe Tocilizumab et 52 patients dans le groupe soins courants. L’âge moyen était de 68,9 ± 2 ans et 71 % des patients étaient des hommes. Les patients du groupe Tocilizumab étaient plus fréquemment diabétique (34 % vs 13 % ; p = 0,02), et avaient un niveau d’oxygène moyen plus élevé (9,1 L/min vs 6,8 L/min ; p = 0,0002). Les patients du groupe Tocilizumab avaient reçu plus de corticoïdes que les patients du groupe soins courants (53 % vs 6 % ; p < 0,0001). Le délai de sevrage en oxygène n’était pas diffèrent dans les deux groupes, 14,1 [IQR 7-19] jours dans le groupe Tocilizumab versus 12,2 [IQR 7,5-14] jours dans le groupe soins courants, hazard ratio ajusté à 1,53 (IC95 % (0,96-2,45) ; p = 0,073). Il n’y avait pas non plus de différence concernant les critères de jugement secondaires. Discussion Dans cet essai, nous rapportons une absence de bénéfice du Tocilizumab dans les formes modérées à sévères de la COVID-19. L’injection de Tocilizumab à la posologie de 8 mg/kg n’améliorait pas le délai de sevrage en oxygène, et ne réduisait pas la nécessité d’intubation, de transfert en soins intensifs ou la mortalité. Cette absence de différence peut être expliquée, en partie, par le fait que les patients du groupe Tocilizumab étaient plus graves (oxygéno-requerance plus élevée) et comorbides (plus fréquemment diabétiques). En revanche, ces patients avaient reçu plus de corticoides qui est aujourd’hui un traitement recommandé dans la prise en charge des patients sous oxygène, atteints de la COVID-19. Notre étude manque aussi de puissance, une récente méta-analyse estimait à 2300 patients (dans chaque bras) le nombre de sujet nécessaire pour mettre en évidence une différence significative si celle-ci existait. Conclusion Un essai randomisé récent qui incluait un nombre de sujet suffisant, en cours de publication, a montré des résultats encourageants, avec une diminution de la mortalité à 28 jours chez les patients traités par Tocilizumab (majoritairement en associations au corticoïdes). Toutefois la question du meilleur moment de l’injection de Tocilizumab chez les patients atteints de COVID-19 reste entière.
Collapse
|
9
|
Giraud S, Bardel C, Dupuis-Girod S, Carette MF, Gilbert-Dussardier B, Riviere S, Saurin JC, Eyries M, Patri S, Decullier E, Calender A, Lesca G. Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2020; 15:254. [PMID: 32962750 PMCID: PMC7507685 DOI: 10.1186/s13023-020-01533-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 09/07/2020] [Indexed: 11/23/2022] Open
Abstract
Background Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disorder characterized by multiple telangiectases and caused by germline disease-causing variants in the ENG (HHT1), ACVRL1 (HHT2) and, to a lesser extent MADH4 and GDF2, which encode proteins involved in the TGF-β/BMP9 signaling pathway. Common visceral complications of HHT are caused by pulmonary, cerebral, or hepatic arteriovenous malformations (HAVMs). There is large intrafamilial variability in the severity of visceral involvement, suggesting a role for modifier genes. The objective of the present study was to investigate the potential role of ENG, ACVRL1, and of other candidate genes belonging to the same biological pathway in the development of HAVMs. Methods We selected 354 patients from the French HHT patient database who had one disease causing variant in either ENG or ACVRL1 and who underwent hepatic exploration. We first compared the distribution of the different types of variants with the occurrence of HAVMs. Then, we genotyped 51 Tag-SNPs from the Hap Map database located in 8 genes that encode proteins belonging to the TGF-β/BMP9 pathway (ACVRL1, ENG, GDF2, MADH4, SMAD1, SMAD5, TGFB1, TGFBR1), as well as in two additional candidate genes (PTPN14 and ADAM17). We addressed the question of a possible genetic association with the occurrence of HAVMs. Results The proportion of patients with germline ACVRL1 variants and the proportion of women were significantly higher in HHT patients with HAVMs. In the HHT2 group, HAVMs were more frequent in patients with truncating variants. Six SNPs (3 in ACVRL1, 1 in ENG, 1 in SMAD5, and 1 in ADAM17) were significantly associated with HAVMs. After correction for multiple testing, only one remained significantly associated (rs2277383). Conclusions In this large association study, we confirmed the strong relationship between ACVRL1 and the development of HAVMs. Common polymorphisms of ACVRL1 may also play a role in the development of HAVMs, as a modifying factor, independently of the disease-causing variants.
Collapse
Affiliation(s)
- Sophie Giraud
- Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, 69677, Bron, France
| | - Claire Bardel
- Service de Biostatistique-Bioinformatique, plateforme de séquençage à haut débit, Hospices Civils de Lyon, Lyon, France.,Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.,CNRS UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biotatistique-Santé, F-69100, Villeurbanne, France
| | - Sophie Dupuis-Girod
- Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, 69677, Bron, France.,Centre de Référence National pour la maladie de Rendu-Osler, Groupement Hospitalier Est, Bron, France
| | | | | | - Sophie Riviere
- CHU de Montpellier, Service de Médecine Interne, Hôpital St Eloi, Montpellier, France
| | - Jean-Christophe Saurin
- Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.,Hospices Civils de Lyon, Service de Gastro-Entérologie, Hôpital E. Herriot, Lyon, France
| | - Mélanie Eyries
- Assistance Publique-Hôpitaux de Paris, Département de Génétique, GH Pitié-Salpêtrière, Paris, France
| | - Sylvie Patri
- CHU la Milétrie, Laboratoire de Génétique, Poitiers, France
| | - Evelyne Decullier
- Unité de recherche clinique du pole IMER of the Hospices Civils de Lyon, Lyon, France
| | - Alain Calender
- Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, 69677, Bron, France.,Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.,Equipe EA7426, Immunopathologie des voies respiratoires, Université Lyon 1, Lyon, France
| | - Gaëtan Lesca
- Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier Est, 69677, Bron, France. .,Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne, France.
| |
Collapse
|
10
|
Catano J, Guedon A, Riviere S, Carrat F, Mahevas T, Fain O, Mekinian A. [Cancers in systemic sclerosis : risk factors, impact on survival and literature review]. Rev Med Interne 2019; 40:637-644. [PMID: 31255252 DOI: 10.1016/j.revmed.2019.06.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 06/11/2019] [Accepted: 06/11/2019] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Patients with systemic sclerosis (SSc) have an increased risk of malignancy. In this study, we aimed to analyze the prevalence of cancer, the risk factors and the impact on overall survival. PATIENTS AND METHODS We analyzed clinical (history of cancer, toxic exposition, organ involvement), immunological and treatment data in a monocentric cohort of SSc patients followed between January 2004 and December 2017. RESULTS Two hundred and ten patients with SSc were included. During the follow-up, twenty-one patients (10 %) were diagnosed with malignancies. The underlying malignancies were breast adenocarcinoma (n=6, 28%), lung cancer (n=6, 28%), colorectal (colic adenocarcinoma, carcinoid tumor of the appendix), ovarian and cervix uteri, melanoma, kidney and papillary thyroid carcinoma (one of each). The median time between the first visit and the diagnosis of cancer was 4 [2-10] years. The overall survival in SSc patients with cancer was not significantly different from patients without cancer, with median survival during the first quartile (75%) at 12 years for patients with cancer and 11.6 years for those without cancer (P=0.9). The history of renal scleroderma crisis (HR 10.99, IC95% [1.95-62.07]; P=0.006) and the presence of anti-topoisomerase I antibodies (HR 5.5, IC95% [1.40-21.67]; P=0.01) were associated with an increased risk of cancer, whereas the presence of gastroesophageal reflux was inversely associated with the cancer occurrence (HR 0.22, IC95% [0.056-0.867]; P=0.03). CONCLUSION The history of renal scleroderma crisis and the positivity of anti-topoisomerase I antibodies were associated with an increased risk of cancer in SSc patients in this monocentric study.
Collapse
Affiliation(s)
- J Catano
- Sorbonne universités, UPMC université Paris 06, service de médecine interne, département hospitalo-universitaire inflammation-immunopathologie-biotherapie (DHU i2B), Paris 75005, France
| | - A Guedon
- Service de biostatistiques, Institut Pierre-Louis d'épidémiologie et de santé publique IPLESP, AP-HP, hôpital Saint-Antoine, Paris 75012, France
| | - S Riviere
- Sorbonne universités, UPMC université Paris 06, service de médecine interne, département hospitalo-universitaire inflammation-immunopathologie-biotherapie (DHU i2B), Paris 75005, France
| | - F Carrat
- Service de biostatistiques, Institut Pierre-Louis d'épidémiologie et de santé publique IPLESP, AP-HP, hôpital Saint-Antoine, Paris 75012, France
| | - T Mahevas
- Sorbonne universités, UPMC université Paris 06, service de médecine interne, département hospitalo-universitaire inflammation-immunopathologie-biotherapie (DHU i2B), Paris 75005, France
| | - O Fain
- Sorbonne universités, UPMC université Paris 06, service de médecine interne, département hospitalo-universitaire inflammation-immunopathologie-biotherapie (DHU i2B), Paris 75005, France
| | - A Mekinian
- Sorbonne universités, UPMC université Paris 06, service de médecine interne, département hospitalo-universitaire inflammation-immunopathologie-biotherapie (DHU i2B), Paris 75005, France.
| |
Collapse
|
11
|
Ricard L, Jachiet V, Couture P, Malard F, Riviere S, Senet P, Monfort J, Fain O, Mohty M, Gaugler B, Mekinian A. Les lymphocytes T folliculaires helper circulants sont augmentés dans la sclérodermie systémique et activent la différenciation des plasmablastes à l’aide de l’IL-21 qui peut être inhibée par le ruxolitinib. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Cacciatore C, Riviere S, Cohen A, Gatfosse M, Ederhy S, Fain O, Mekinian A. Sclérodermie systémique : efficacité des immunoglobulines intraveineuses pour l’atteinte cardiaque sévère ? Rev Med Interne 2018; 39:594-596. [DOI: 10.1016/j.revmed.2017.12.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 12/28/2017] [Accepted: 12/28/2017] [Indexed: 01/22/2023]
|
13
|
Thiebaut M, Launay D, Riviere S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacité et tolérance du rituximab dans la sclérodermie systémique : étude rétrospective et revue de la littérature. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.03.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
14
|
Riviere S, Delmas MC, Iwatsubo Y. [Asthma and socioeconomic characteristics in France in 2012]. Rev Mal Respir 2018; 35:287-294. [PMID: 29602479 DOI: 10.1016/j.rmr.2017.12.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Accepted: 12/05/2017] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The prevalence of adult asthma is around 6-7% in France. This disease is multifactorial and is related in particular to occupational factors. Using data from The French Health, Health Care and Insurance Survey (ESPS), this study aimed to describe asthma prevalence in France according to socio-economic status in 2012. METHODS This analysis included the population aged 15 years and over. Current asthma, defined by a declaration of having asthma in the last 12 months, was analyzed according to socio-economic variables available in the ESPS survey. RESULTS Among the 23,047 subjects interviewed, 12,565 were included in the analysis. Current asthma frequency was 7.4%. Higher risk of asthma was observed in unemployed, non-qualified persons, with a lower income, or having free healthcare insurance. Regarding occupations, in men, trade and commerce employees, personal services employees and administrative employees were associated with a higher level of current asthma prevalence. CONCLUSIONS These results show that subjects with lower socio-economic status are more likely to suffer from asthma. New epidemiological tools in France, including cohorts (Constances, COSET) will be helpful to study more precisely the associations between asthma and occupational factors.
Collapse
Affiliation(s)
- S Riviere
- Santé publique France, 94415 Saint-Maurice, France.
| | - M-C Delmas
- Santé publique France, 94415 Saint-Maurice, France
| | - Y Iwatsubo
- Santé publique France, 94415 Saint-Maurice, France
| |
Collapse
|
15
|
Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol 2017; 68:1522-30. [PMID: 27015607 DOI: 10.1002/art.39667] [Citation(s) in RCA: 104] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 02/25/2016] [Indexed: 01/09/2023]
Abstract
OBJECTIVE To analyze the factors associated with response to anti-tumor necrosis factor (anti-TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients with refractory noninfectious uveitis. METHODS This was a multicenter observational study of 160 patients (39% men and 61% women; median age 31 years [interquartile range 21-42]) with uveitis that had been refractory to other therapies, who were treated with anti-TNF (IFX 5 mg/kg at weeks 0, 2, 6, and then every 5-6 weeks [n = 98] or ADA 40 mg every 2 weeks [n = 62]). Factors associated with complete response were assessed by multivariate analysis. Efficacy and safety of IFX versus ADA were compared using a propensity score approach with baseline characteristics taken into account. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (95% CIs) were calculated. RESULTS The main etiologies of uveitis included Behçet's disease (BD) (36%), juvenile idiopathic arthritis (22%), spondyloarthropathy (10%), and sarcoidosis (6%). The overall response rate at 6 and 12 months was 87% (26% with complete response) and 93% (28% with complete response), respectively. The median time to complete response was 2 months. In multivariate analysis, BD and occurrence of >5 uveitis flares before anti-TNF initiation were associated with complete response to anti-TNF (SHR 2.52 [95% CI 1.35-4.71], P = 0.004 and SHR 1.97 [95% CI 1.02-3.84], P = 0.045, respectively). Side effects were reported in 28% of patients, including serious adverse events in 13%. IFX and ADA did not differ significantly in terms of occurrence of complete response (SHR 0.65 [95% CI 0.25-1.71], P = 0.39), serious side effects (SHR 0.22 [95% CI 0.04-1.25], P = 0.089), or event-free survival (SHR 0.55 [95% CI 0.28-1.08], P = 0.083). CONCLUSION Anti-TNF treatment is highly effective in refractory inflammatory uveitis. BD is associated with increased odds of response. IFX and ADA appear to be equivalent in terms of efficacy.
Collapse
Affiliation(s)
- Hélène Vallet
- Hôpital Pitié-Salpêtrière, AP-HP, Centre National de Référence Maladies Systémiques et Autoimmunes Rares, and Université Paris VI, Paris, France
| | | | - Lucie Biard
- Hôpital Saint Louis and Le Centre de Recherche INSERM, Paris Sorbonne Cité, UMR 1153, Paris, France
| | | | | | | | | | | | - Aude Rigolet
- Hôpital Pitié-Salpêtrière, AP-HP, Centre National de Référence Maladies Systémiques et Autoimmunes Rares, and Université Paris VI, Paris, France
| | - Alban Deroux
- CHU de Grenoble-Hôpital Michallon, Grenoble, France
| | | | | | | | | | - Eric Hachulla
- Eric Hachulla, MD, PhD: Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | | | | | | | - Pierre-Alban Bouche
- Hôpital Saint Louis and Le Centre de Recherche INSERM, Paris Sorbonne Cité, UMR 1153, Paris, France
| | | | - Gregory Pugnet
- CHU de Toulouse-Hôpital Purpan, INSERM UMR 1027, Toulouse, France
| | | | - Matthieu Resche Rigon
- Hôpital Saint Louis and Le Centre de Recherche INSERM, Paris Sorbonne Cité, UMR 1153, Paris, France
| | - Patrice Cacoub
- Hôpital Pitié-Salpêtrière, AP-HP, Centre National de Référence Maladies Systémiques et Autoimmunes Rares, and Université Paris VI, Paris, France
| | | | - David Saadoun
- Hôpital Pitié-Salpêtrière, AP-HP, Centre National de Référence Maladies Systémiques et Autoimmunes Rares, and Université Paris VI, Paris, France
| | | |
Collapse
|
16
|
Sanges S, Riviere S, Mekinian A, Martin T, Le Quellec A, Chatelus E, Lescoat A, Quéméneur T, Deroux A, Hatron P, Hachulla E, Launay D. Utilisation des immunoglobulines intraveineuses au cours de la sclérodermie systémique : étude rétrospective multicentrique. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Tall F, Dechomet M, Riviere S, Cottin V, Ballot E, Tiev KP, Montin R, Morin C, Chantran Y, Grange C, Jullien D, Ninet J, Chretien P, Cabane J, Fabien N, Johanet C. The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis. Scand J Immunol 2017; 85:73-79. [PMID: 27864990 DOI: 10.1111/sji.12510] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 11/10/2016] [Indexed: 11/28/2022]
Abstract
Systemic sclerosis (SSc) is a heterogeneous autoimmune disease associated with several antinuclear autoantibodies useful to diagnosis and prognosis. The aim of the present multicentric study was to determine the clinical relevance of antifibrillarin autoantibodies (AFA) in patients with SSc. The clinical features of 37 patients with SSc positive for AFA (AFA+) and 139 SSc patients without AFA (AFA-) were collected retrospectively from medical records to enable a comparison between AFA- and AFA+ patients. Antifibrillarin autoantibodies were screened by an indirect immunofluorescence technique using HEp2 cells and identified by an in-house Western blot technique and/or an EliA test. Comparing AFA+ and AFA- patients, AFA+ patients were significantly younger at disease onset (36.9 versus 42.9; P = 0.02), more frequently male (P = 0.02) and of Afro-Caribbean descent (65% versus 7.7%; P < 0.001). At diagnosis, the Rodnan skin score evaluating the cutaneous manifestations was higher (13.3 versus 8.7; P = 0.01) and myositis was also more common in the AFA+ group (31.4% versus 12.2%; P < 0.01). Patients with AFA+ were not associated with diffuse cutaneous SSc or with lung involvement and no difference in survival was observed. Antifibrillarin autoantibodies are associated with patients of Afro-Caribbean origin and can identify patients with SSc who are younger at disease onset and display a higher prevalence of myositis.
Collapse
Affiliation(s)
- F Tall
- Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - M Dechomet
- Immunology Department, Lyon-Sud Hospital, Hospices Civils de Lyon; Claude Bernard, Pierre-Benite, France
| | - S Riviere
- Internal Medicine Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - V Cottin
- Respiratory Diseases Department, Louis Pradel Hospital, Bron, France
| | - E Ballot
- Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - K P Tiev
- Internal Medicine Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - R Montin
- Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - C Morin
- Internal Medicine Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - Y Chantran
- Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - C Grange
- Internal Medicine Department, Lyon-Sud Hospital, Pierre-Bénite, France
| | - D Jullien
- Dermatology Department, Edouard Herriot Hospital, Lyon, France
| | - J Ninet
- Internal Medicine Department, Edouard Herriot Hospital, Lyon, France
| | - P Chretien
- Immunology Department, AP-HP Bicêtre Hospital, Kremlin Bicêtre, France
| | - J Cabane
- Internal Medicine Department, AP-HP Saint-Antoine Hospital, Paris, France
| | - N Fabien
- Immunology Department, Lyon-Sud Hospital, Hospices Civils de Lyon; Claude Bernard, Pierre-Benite, France.,University Lyon I, University of Lyon, Pierre-Bénite, France
| | - C Johanet
- Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France.,UFR 967, Faculte de medecine, University Pierre et Marie Curie, Paris6, France
| |
Collapse
|
18
|
Riviere S, Du Pasquier - Fediaevsky L, Andrei S, Abou Nakad S, Berche M, Héron E. Faibles doses de rituximab dans le traitement des orbitopathies basedowiennes réfractaires. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun 2015; 62:67-74. [PMID: 26162757 DOI: 10.1016/j.jaut.2015.06.005] [Citation(s) in RCA: 143] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Revised: 06/06/2015] [Accepted: 06/07/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD). METHODS We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years]. RESULTS Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2 ± 0.5 vs 1.7 ± 2.4 before the use of anti-TNF, p < 0.0001). The prednisone dose was significantly reduced at 6 and 12 months (p < 0.0001). In multivariate analysis, retinal vasculitis was negatively associated with complete response to anti-TNF (OR = 0.33 [0.12-0.89]; p = 0.03). The efficacy and relapse free survival were similar regardless of the type of anti-TNF agent used. After a median follow-up of 21 [7-36] months, side effects were reported in 28% of patients, including infections (16.3%) and hypersensitivity reactions (4.1%). Serious adverse events were reported in 13% of cases. CONCLUSION Anti-TNF alpha therapy is efficient in all severe and refractory BD manifestations. Efficacy appears to be similar regardless of the anti-TNF agent used (infliximab or adalimumab).
Collapse
Affiliation(s)
- H Vallet
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière hospital, 83, boulevard de l'Hôpital, Paris 75013, France; Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France
| | - S Riviere
- Department of Internal Medicine, Saint Eloi Hospital, Montpellier, France
| | - A Sanna
- Department of Clinical Epidemiology and Biostatistics, Saint Louis Hospital, France
| | - A Deroux
- Department of Internal Medicine, University Hospital, Grenoble, France
| | - G Moulis
- Department of Internal Medicine, University Hospital, Toulouse, France
| | - O Addimanda
- Department of Rheumatology, Santa Maria Nuova Hospital, Reggio Emilia, Italy
| | - C Salvarani
- Department of Rheumatology, Santa Maria Nuova Hospital, Reggio Emilia, Italy
| | - M Lambert
- Department of Internal Medicine, University Hospital, Lille, France
| | - P Bielefeld
- Department of Internal Medicine, University Hospital, Dijon, France
| | - P Seve
- Department of Internal Medicine, Croix Rousse Hospital, Lyon, France
| | - J Sibilia
- Department of Rheumatology, University Hospital, Strasbourg, France
| | - Jl Pasquali
- Department of Internal Medicine, University Hospital, Strasbourg, France
| | - Jb Fraison
- Department of Internal Medicine, Jean Verdier Hospital, Bondy, France
| | - I Marie
- Department of Internal Medicine, University Hospital, Rouen, France
| | - L Perard
- Department of Internal Medicine, Edouard Herriot Hospital, Lyon, France
| | - L Bouillet
- Department of Internal Medicine, University Hospital, Grenoble, France
| | - F Cohen
- Department of Internal Medicine, E3M Institut, Pitié Salpêtrière Hospital, Paris, France
| | - D Sene
- Department of Internal Medicine, Lariboisière Hospital, Paris, France
| | - Y Schoindre
- Department of Internal Medicine, Pitié Salpêtrière Hospital, Paris, France
| | - O Lidove
- Department of Internal Medicine, Croix Saint Simon Hospital, Paris, France
| | - P Le Hoang
- Department of Ophtalmology, Pitié Salpêtrière Hospital, Paris, France
| | - E Hachulla
- Department of Internal Medicine, University Hospital, Lille, France
| | - O Fain
- Department of Internal Medicine, Saint Antoine Hospital, Paris, France
| | - X Mariette
- Department of Rheumatology, Kremlin Bicetre University Hospital, Kremlin Bicetre, France
| | - T Papo
- Department of Internal Medicine, Bichat Hospital, Paris, France
| | - B Wechsler
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière hospital, 83, boulevard de l'Hôpital, Paris 75013, France; Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France
| | - B Bodaghi
- Department of Ophtalmology, Pitié Salpêtrière Hospital, Paris, France
| | - M Resche Rigon
- Department of Clinical Epidemiology and Biostatistics, Saint Louis Hospital, France
| | - P Cacoub
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière hospital, 83, boulevard de l'Hôpital, Paris 75013, France; Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France
| | - D Saadoun
- Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière hospital, 83, boulevard de l'Hôpital, Paris 75013, France; Centre national de référence maladies systémiques et autoimmunes rares, DHU Inflammation, Immunopathologie, Biothérapie, Université Paris VI-Pierre et Marie Curie, Paris, France.
| | | |
Collapse
|
20
|
Vallet H, Riviere S, Lambert M, Deroux A, Bielfeld P, Seve P, Fraison J, Perard L, Schoindre Y, Papo T, Kaplanski G, Sellam J, Le Hoang T, Fain O, Marie I, Sene D, Mariette X, Blaison G, Hachulla E, Perlat A, Wechsler B, Cacoub P, Bodaghi B, Saadoun D. SAT0269 Efficacy and Safety of Anti-TNF Alpha in BehÇEt Disease: Preliminary Results of A French Multicenter Registry of 92 Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
Vallet H, Seve P, Riviere S, Perard L, Bielefeld P, Abad S, Rigolet A, Perlat A, Fain O, Bienvenu B, Le Hoang T, Sene D, Tieulie N, Wechsler B, Chapelon C, Fraison J, Schoindre Y, Bodaghi B, Cacoub P, Saadoun D. THU0379 Efficacy and Safety of Anti-TNF Alpha in NON Infectious Inflammatory Uveitis: Preliminary Results of A French Multicenter Registry of 162 Patients. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.6013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Abdo L, Gatfossé M, Riviere S, Cabane J. Occlusion digestive haute récidivante. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Partouche L, Riviere S, Mura F, Le Quellec A. Mydriase bilatérale hyporéactive définitive induite par la moxifloxacine. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Humbert S, Guilpain P, Altwegg R, Terrier B, Riviere S, Mahr A, Puechal X, Le Quellec A, Guillevin L. Association entre les vascularites ANCA-positives et les maladies inflammatoires chroniques de l’intestin : à propos de 11 cas. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
25
|
Goulabchand R, Khellaf L, Costes V, Foulongne V, Riviere S, Forestier A, Le Quellec A, Guilpain P. Sclérodermie induite par le Cytomégalovirus (CMV) : rôle potentiel des lymphocytes NK. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.10.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Affiliation(s)
- S. Riviere
- PIMM laboratory; Arts et Métiers ParisTech; CNRS-UMR 8006 151 Bd de l'hôpital 75013 Paris France
| | - S. Khelladi
- DynFluid Laboratory; Arts et Métiers ParisTech; 151 Bd de l'hôpital 75013 Paris France
| | - S. Farzaneh
- PIMM laboratory; Arts et Métiers ParisTech; CNRS-UMR 8006 151 Bd de l'hôpital 75013 Paris France
| | - F. Bakir
- DynFluid Laboratory; Arts et Métiers ParisTech; 151 Bd de l'hôpital 75013 Paris France
| | - A. Tcharkhtchi
- PIMM laboratory; Arts et Métiers ParisTech; CNRS-UMR 8006 151 Bd de l'hôpital 75013 Paris France
| |
Collapse
|
27
|
Dufour S, Riviere S, Schiffmann A, Forestier A, Guilpain P, Le Quellec A. Syndrome d’hyperimmunoglobulinémie D et anakinra : à propos de 2 cas. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Cerutti D, Riviere S, Kavian N, Khau Van Kien-Wautot A, Quere I, Vincent T, Borderie D, Batteux F, Le Quellec A, Guilpain P. Stress oxydant et prolifération cellulaire au cours de la sclérodermie systémique et de la maladie de Rendu-Osler : étude comparative chez 60 patients. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Veysseyre F, Schiffmann A, Riviere S, Forestier A, Ramos J, Guilpain P, Le Quellec A. Hypertension portale sans cirrhose au cours d’une vascularite des petits vaisseaux : penser à l’hyperplasie nodulaire régénérative. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Lam M, Jammal M, Tiev K, Toledano C, Fardet L, Riviere S, Josselin Mahr L, Cabane J, Kettaneh A. [Pulmonary embolism revealed by a seizure: a case report and literature review]. Rev Med Interne 2012; 33:457-60. [PMID: 22770576 DOI: 10.1016/j.revmed.2012.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Revised: 05/11/2012] [Accepted: 06/03/2012] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Pulmonary embolism is a frequent disorder with a diagnostic approach based on probability estimation. Nevertheless, in some cases, prognosis may be impaired by delayed diagnosis resulting from atypical presenting manifestations. CASE REPORT We report a 37-year-old woman, admitted for a seizure as the presenting manifestation of pulmonary embolism, and review nine additional similar cases reported in the literature since 1945. Seizures were always generalized tonico-clonic in nature without a past medical history of epilepsy in any case. Tachycardia was noted in nine patients over ten. Prognosis was usually severe leading to death by cardiovascular deficiency in 70% of cases. CONCLUSION These observations suggest a systematic suspicion of pulmonary embolism in the presence of generalized convulsion with persistent tachycardia after resolution of the episode and no past medical history of seizures. More research is necessary to assess the role of d-dimer testing in these situations.
Collapse
Affiliation(s)
- M Lam
- Service de médecine interne, université Pierre-et-Marie-Curie Paris, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 184 rue du Faubourg-Saint-Antoine, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Maria A, Guilpain P, Forestier A, Delhom E, Schiffmann A, Riviere S, Khau Van Kien A, Leray-Moragues H, Serre I, Vincent T, Eliaou J, Le Quellec A. Embolie pulmonaire asymptomatique dans le syndrome de Churg et Strauss. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Maria A, Guilpain P, Forestier A, Schiffmann A, Riviere S, Oziol E, Frouin E, Le Quellec A. Syndrome de Sweet et sarcoïdose : une association inhabituelle. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Jammal M, Lam M, Tiev K, Toledano C, Fardet L, Riviere S, Josselin-Mahr L, Cabane J, Kettaneh A. Embolie pulmonaire révélée par une crise convulsive : à propos d’un cas et revue de la littérature. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Provost D, Cerazin C, Riviere S, Debarre J, Sillam F, Benaim A, Latchmun P, Eloy A, Fernet F, Tassy V, Cadeac-Birman H, Berson C, Cervantes M, Brom M, Marguet G, Rousseau S, Albouy J, Valenty M. Programme de surveillance des maladies à caractère professionnel : comparaison interrégionale en 2008. ARCH MAL PROF ENVIRO 2012. [DOI: 10.1016/j.admp.2012.03.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Lefèvre-Utile A, Kettaneh A, Tiev K, Josselin L, Riviere S, Fardet L, Cabane J, Toledano C. Une entité clinique sous-diagnostiquée : la dermatose pustuleuse et érosive des jambes. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Riviere S, Dinh Xuan A, Hua-Huy T, Kettaneh A, Cabane J, Tiev KP. Une concentration alvéolaire de monoxyde d’azote supérieure à 8,5ppb identifie les patients sclérodermiques avec fibrose pulmonaire répondeurs au traitement immunosuppresseur. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Mauhin W, Riviere S, Prat L, Cabane J, Tiev K. Régression de la fibrose pulmonaire au cours d’une scléromyosite par des cures d’immunoglobulines intraveineuses. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.03.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Pasquet F, Kodjikian L, Mura F, Riviere S, Harroche J, Blanc AP, Chaix F, Oksenhendler E, Seve P. Uveitis and Common Variable Immunodeficiency: Data from the DEF-I Study And Literature Review. Ocul Immunol Inflamm 2012; 20:163-70. [DOI: 10.3109/09273948.2012.674612] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
39
|
Farzaneh S, Riviere S, Tcharkhtchi A. Rheokinetic of polyurethane crosslinking time-temperature-transformation diagram for rotational molding. J Appl Polym Sci 2012. [DOI: 10.1002/app.34932] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
40
|
Fraison JB, Guilpain P, Schiffmann A, Forestier A, Riviere S, Veyrac M, Lemoing V, Rispail P, Le Quellec A. Exposition aux fientes de poulets et crytococcose pulmonaire au cours de la maladie de Crohn traitée par anti-TNF. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
41
|
Schiffmann A, Guilpain P, Ramos J, Forestier A, Riviere S, Le Quellec A. La pseudo-obstruction intestinale chronique : une manifestation rare mais sévère de dermatomyosite. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Schiffmann A, Fontaine C, Guilpain P, Morel J, Guillot B, Girard C, Riviere S, Le Quellec A. Lésions hépatiques induites par le méthotrexate : intérêt des méthodes non invasives de surveillance. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
43
|
Cavigioli S, Bessis D, Riviere S, Guilpain P, Le Quellec A. Espoir thérapeutique des xanthogranulomes : les immunoglobulines intraveineuses. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
44
|
Kluger N, Riviere S, Mura F, Guillot B, Girard C. Simultaneous occurrence of generalized granuloma annulare, anterior uveitis and giant cell arteritis: coincidental or not? Presse Med 2011; 41:548-9. [PMID: 21964039 DOI: 10.1016/j.lpm.2011.08.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2011] [Revised: 08/09/2011] [Accepted: 08/31/2011] [Indexed: 11/26/2022] Open
|
45
|
Lacroix MC, Rodriguez-Enfedaque A, Grébert D, Laziz I, Meunier N, Monnerie R, Persuy MA, Riviere S, Caillol M, Renaud F. Insulin but not leptin protects olfactory mucosa from apoptosis. J Neuroendocrinol 2011; 23:627-40. [PMID: 21554433 DOI: 10.1111/j.1365-2826.2011.02154.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The mammalian olfactory mucosa (OM) is continually renewed throughout life. Owing to their position in the nasal cavity, OM cells are exposed to multiple insults, including high levels of odourants that can induce their death. OM regeneration is therefore essential to maintain olfactory function, and requires the tight control of both cell death and proliferation. Apoptosis has been implicated in OM cell death. Olfaction is one of the senses involved in food intake and depends on individual nutritional status. We have previously reported the influence of hormones related to nutritional status on odour perception and have shown that the OM is a target of insulin and leptin, two hormones known for their anti-apoptotic properties. In the present study, we investigated the potential anti-apoptotic effect of these metabolic hormones on OM cells. Both Odora cells (an olfactive cell line) and OM cells treated with etoposide, a p53 activity inducer, exhibited mitochondrial-dependent apoptosis that was inhibited by the pan-caspase inhibitor zVAD-fmk. Insulin, but not leptin, impaired this apoptotic effect. Insulin addition to the culture medium reduced p53 phosphorylation, caspase-3 and caspase-9 cleavage, and caspase-3 enzymatic activity induced by etoposide. The apoptotic wave observed in the OM after interruption of the neuronal connections between the OM and the olfactory bulb by bulbectomy was impaired by intranasal insulin treatment. These findings suggest that insulin may be involved in OM cellular dynamics, through endocrine and/or paracrine-autocrine effects of circulating or local insulin, respectively.
Collapse
Affiliation(s)
- M-C Lacroix
- INRA, UMR 1197 Neurobiologie de l'Olfaction et Modélisation en Imagerie, Jouy en Josas, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Tiev K, Ledong N, Riviere S, Kettaneh A, Hua-Huy T, Duong-Quy S, Dinh-Xuan A, Cabane J. Prédiction de la survenue de l’hypertension pulmonaire au cours de la sclérodermie systémique par le coefficient de diffusion de la membrane alvéolaire. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
47
|
Riviere S, Fabresse N, Roubille C, Le Quellec A. Éducation thérapeutique du patient : enquête préliminaire. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
48
|
Fraison JB, Riviere S, Konate AP, Schiffmann A, Mura F, Le Quellec A. Uvéite intermédiaire corticorésistante : pensez à l’amylose. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Greslou F, Fontaine C, Roubille C, Riviere S, Godeau B, Le Quellec A. Efficacité du Rituximab sur les lésions granulomateuses associées au déficit immunitaire commun variable. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Forestier A, Jeziorski E, Roubille C, Riviere S, Navarro R, Le Moing V, Jorgensen C, Le Quellec A. Les manifestations auto-immunes chez les patients atteints de déficit immunitaire commun variable ou de déficit sélectif en IgA : étude rétrospective monocentrique de 15 observations. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|